WEIS MARKETS REPORTS SECOND QUARTER 2026 RESULTS
WEIS MARKETS INC (WMK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE Contact: Dennis Curtin Weis Markets, Inc. 570-847-3636 dennis.curtin@weismarkets.com WEIS MARKETS REPORTS SECOND QUARTER 2026 RESULTS Second Quarter 2026 total revenue increased 4.6% and comparable store sales increased 2.
How this was made
The 30-second read
Why it matters
Key new information is the magnitude of pharmacy revenue headwinds tied to the Inflation Reduction Act Medicare maximum fair price provisions (effective Jan. 1, 2026), alongside reported revenue, net income, and EPS changes versus the prior year.
Market read
Traders can update WMK’s earnings/margin expectations using the disclosed regulatory headwind and the reported net income decline despite revenue and comparable sales growth.
What to watch
The release does not provide guidance or a forward pharmacy margin outlook; traders may need to infer whether the headwind is stabilizing or worsening in subsequent quarters.
Background
This is an SEC 8-K with the company’s earnings release for the 13-week second quarter and 26-week year-to-date ended June 27, 2026, plus a declared quarterly cash dividend.
Ticker impact
Weis Markets reported 2Q26 revenue of $1.28B (+4.6%) and noted pharmacy revenue headwinds of about $10.71M from IRA Medicare pricing provisions effective Jan. 1, 2026.
Near-term bias modestly negative to neutral as investors weigh revenue growth against the disclosed pharmacy pricing headwind and net income decline.
The filing provides concrete financial results (revenue, net income, EPS) and a named regulatory-driven headwind amount, which can affect margin expectations for pharmacy and overall earnings power.
Market effects
Highlights how IRA Medicare maximum fair price provisions are pressuring grocery/pharmacy operators’ pharmacy revenue and potentially margins.
Relevant for Mid-Atlantic grocery retail peers with similar pharmacy exposure to Medicare pricing rules.
Limited, primarily a US retail/pharmacy regulatory read-through.
Counterpoint
The disclosed pharmacy headwind is quantified, but comparable store sales still grew, suggesting operating execution may offset some regulatory pressure.
Key entities
- companyWeis Markets, Inc.
NYSE-listed grocery retailer reporting 2Q26 and 26-week results, including IRA-related pharmacy pricing headwinds and a quarterly dividend.
- regulationInflation Reduction Act (IRA) Medicare maximum fair price provisions
Policy effective Jan. 1, 2026 that created pharmacy pricing headwinds quantified in the release.
